07:00 , Jun 16, 2014 |  BioCentury  |  Finance

Hoping for a Cinderella moment

Investors flooded into Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) last week to get a piece of the lone biotech with unpartnered clinical-stage HCV assets. However, at least one buysider thinks Achillion missed its window of opportunity. Achillion...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Clinical News

ACH-3102: Additional Phase II data

Additional data from the 12-week, double-blind, placebo-controlled, U.S. and Canadian Phase II 007 trial in 30 treatment-naïve patients with chronic HCV genotype 1 infection showed that 100% of patients with HCV genotype 1b infection who...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Clinical News

Sovaprevir: Additional Phase II data

Additional data from the 12-week, double-blind, placebo-controlled, U.S. and Canadian Phase II 007 trial in 30 treatment-naïve patients with chronic HCV genotype 1 infection showed that 100% of patients with HCV genotype 1b infection who...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Clinical News

ACH-3102: Additional Phase IIa data

Additional data from 8 treatment-naïve patients with HCV genotype 1b infection carrying the CC genotype of the interleukin-28B (IL-28B; IFNL3 ) gene in an open-label Phase IIa trial showed that oral ACH-3102 plus ribavirin for...
07:00 , Mar 17, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) was off $0.16 to $15.11 last week after submitting an MAA to EMA for Zerenex ferric citrate to treat hyperphosphatemia in dialysis dependent and non-dialysis dependent patients with chronic...
00:21 , Mar 15, 2014 |  BC Extra  |  Clinical News

Achillion reports more HCV data

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) presented additional data from the Phase II 007 trial evaluating the company's ACH-3102 in combination with sovaprevir (formerly ACH-1625 ) to treat chronic HCV genotype 1 infection. In 30 treatment-naïve patients,...
07:00 , Oct 7, 2013 |  BioCentury  |  Finance

Regulatory milestones

Regulatory milestones AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) gained $0.37 to $10.96 last week after submitting an NDA to FDA for Zalviso sufentanil sublingual microtablet system to manage moderate to severe acute pain in a hospital setting....
07:00 , Oct 7, 2013 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
07:00 , Sep 30, 2013 |  BC Week In Review  |  Clinical News

Sovaprevir: FDA hold

Achillion said FDA will not lift a partial clinical hold on HCV compound sovaprevir. In June, FDA placed the hold after a Phase I drug-drug interaction trial showed that sovaprevir plus ritonavir-boosted atazanavir led to...
01:00 , Sep 28, 2013 |  BC Extra  |  Clinical News

FDA refuses to lift sovaprevir hold

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) fell $3.34 (46%) to $3.90 in early after-hours trading after it said late Friday that FDA will not lift a partial clinical hold on HCV compound sovaprevir . In June, FDA...